Pfizer to Cut $3.5B in Costs, Close NJ Plant

There was a time when the world was heavy with anticipation for COVID vaccines and boosters — to the point where desperate consumers were lining up for their chance for an inoculation that was tantamount, for many, to a “get out of quarantine free card.”

But three years past the initial panic of the COVID-19 pandemic, and two years into mass vaccinations, things have stabilized. And while most of it is good for humankind, pharma companies at the forefront of these solutions are now…